Medication-Assisted Treatment (MAT): How It Works and Who It Helps

Medication-assisted treatment, or MAT, is the use of FDA-approved medications — most commonly buprenorphine, methadone, or naltrexone — combined with counseling and behavioral therapy to treat substance use disorders. Decades of research have established MAT as the most effective treatment for opioid use disorder, cutting the risk of fatal overdose by roughly half and significantly improving retention in treatment compared to counseling alone. Despite this evidence, MAT remains underused in the United States because of lingering stigma, access barriers, and the persistent myth that it is "just replacing one drug with another."

What MAT Actually Is

MAT is a clinical approach, not a single medication. It combines three components: (1) an FDA-approved medication that normalizes brain chemistry disrupted by addiction, (2) behavioral counseling to address the psychological, social, and environmental drivers of substance use, and (3) ongoing medical monitoring to ensure safety and adjust treatment as needed. The medications do the biological work of stabilizing the patient; the therapy does the behavioral work of building a life without compulsive drug use. Neither component works as well alone.

MAT is most commonly associated with opioid use disorder, where it has the strongest evidence base, but it also exists for alcohol use disorder (using acamprosate, disulfiram, or naltrexone) and is being studied for stimulant and cannabis use disorders. There is currently no FDA-approved MAT for methamphetamine or cocaine addiction, though clinical trials are ongoing.

How MAT Medications Work

The three main MAT medications for opioid use disorder work through very different mechanisms, and the choice between them depends on the patient's needs, history, and goals.

Buprenorphine (Suboxone, Subutex, Sublocade)

Buprenorphine is a partial opioid agonist. It binds to the same receptors as heroin, fentanyl, or oxycodone, but only partially activates them. This produces enough opioid effect to prevent withdrawal and reduce cravings, but not enough to produce the euphoric high of full agonists. Buprenorphine also has a "ceiling effect" — above a certain dose, taking more does not produce more effect — which dramatically reduces overdose risk compared to methadone or full opioids.

Suboxone combines buprenorphine with naloxone, a pure opioid blocker. When Suboxone is taken as directed (dissolved under the tongue), the naloxone has minimal effect because it is poorly absorbed sublingually. But if someone tries to inject Suboxone to get high, the naloxone kicks in and blocks the effect — a built-in abuse deterrent. Subutex, which is pure buprenorphine without naloxone, is typically used only in pregnancy where naloxone is avoided.

Sublocade is a once-monthly injectable form of buprenorphine administered by a physician. It eliminates the need for daily dosing and reduces diversion risk, making it particularly useful for patients whose home environments make daily medication storage unsafe.

Methadone

Methadone is a full opioid agonist. It fully activates opioid receptors — similar to heroin or oxycodone — but has a long half-life (24-36 hours) and a slow onset, which means it provides steady, non-euphoric opioid effect throughout the day without the peaks and crashes that drive compulsive use. Methadone has been used to treat opioid addiction since the 1960s and remains the most effective MAT medication for severe, long-standing opioid use disorder, particularly in patients who have failed buprenorphine.

The trade-off is that methadone carries real overdose risk, especially during induction (the first week of treatment), and requires daily observed dosing at a federally regulated opioid treatment program (OTP, commonly called a "methadone clinic") for at least the first 90 days. Only after demonstrated stability can patients earn take-home doses.

Naltrexone (Vivitrol)

Naltrexone is an opioid antagonist — the opposite of buprenorphine and methadone. It binds to opioid receptors but does not activate them, and it blocks other opioids from binding. A patient on naltrexone who uses heroin or another opioid will feel nothing, because the drug cannot reach the receptors.

Vivitrol is the injectable form of naltrexone, administered once monthly. Unlike buprenorphine and methadone, naltrexone is not an opioid, so it produces no physical dependence and can be stopped abruptly without withdrawal. The catch is that patients must be fully detoxed from opioids before starting — typically 7-14 days opioid-free — or naltrexone will precipitate severe withdrawal. This detox requirement is the main reason Vivitrol is less widely used than buprenorphine, despite its safety profile.

Who Benefits From MAT

The short answer: almost anyone with moderate to severe opioid use disorder. The American Society of Addiction Medicine, SAMHSA, the CDC, and the World Health Organization all recommend MAT as first-line treatment for opioid use disorder. The evidence is especially strong for these groups:

• People with a history of overdose — MAT significantly reduces overdose mortality, and this is the population with the highest risk
• Pregnant women with opioid use disorder — methadone and buprenorphine are both recommended during pregnancy because the alternative (abstinence-based treatment) carries unacceptable risks to the fetus and the mother
• People returning to the community from incarceration — post-release overdose rates are extraordinarily high, and MAT reduces this risk dramatically
• People with long-term opioid use disorder who have failed abstinence-based treatment multiple times
• People with co-occurring mental illness — MAT provides stability that makes psychiatric treatment possible

MAT may not be the first choice for patients with very brief or mild opioid use histories, those with strong preferences for abstinence-based recovery, or those in occupational situations where any opioid exposure is prohibited. But these are the exception, not the rule.

How Long Should MAT Last?

This is one of the most contested questions in addiction medicine, and the honest answer is: indefinitely, for as long as the patient is benefiting. Research consistently shows that patients who stay on MAT long-term have better outcomes than those who taper off quickly. The CDC and SAMHSA both recommend that MAT duration be determined by clinical response, not by arbitrary timeframes.

Some patients choose to remain on MAT for years or for life, treating opioid use disorder the way a diabetic treats diabetes — as a chronic condition managed with daily medication. Others eventually taper off successfully. Both are legitimate paths, and neither is "more recovered" than the other. The worst outcomes come from patients who taper off too quickly under external pressure (family, employer, legal system) before they are clinically stable, which significantly increases relapse and overdose risk.

Addressing the Stigma

The most persistent objection to MAT is that it "replaces one drug with another." This framing fundamentally misunderstands what addiction is. Opioid use disorder is characterized by compulsive drug-seeking, escalating tolerance, use despite consequences, and loss of control. Someone taking a stable dose of buprenorphine or methadone as prescribed is not experiencing any of those things. They are not seeking drugs compulsively, escalating their dose, or losing control of their behavior. They are taking a medication that normalizes the opioid system the same way insulin normalizes blood glucose in diabetes.

The other common objection is that MAT "enables" addiction by making people "comfortable." This is precisely the point. Withdrawal and cravings are not character-building experiences — they are the neurological manifestation of a disease, and relieving them is how people become capable of the psychological and behavioral work of recovery. You cannot do therapy effectively when you are in acute withdrawal or obsessing over cravings.

If you want a deeper look at one of the supportive medications often used alongside MAT during the initial detox phase, see our guide to clonidine for withdrawal. And if you are dealing with benzodiazepine dependence alongside opioid use disorder — a dangerous but unfortunately common combination — see our guide to benzodiazepine addiction treatment, which must be managed in parallel with MAT.

Finding a MAT Provider

Access to MAT has expanded significantly in recent years. Buprenorphine can now be prescribed by any physician, nurse practitioner, or physician assistant with a DEA registration, without the special "X-waiver" that previously limited prescribing. Methadone is still restricted to federally regulated opioid treatment programs. Vivitrol can be prescribed by any physician.

SAMHSA's findtreatment.gov provides a national directory of MAT providers. Liberation Way's helpline can also help you identify MAT-capable programs near you and walk through the differences between them. The helpline is free, confidential, and available 24 hours a day. Call (866) 275-3142 to speak with a treatment specialist.